MRVI Maravai LifeSciences Holdings, Inc.: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The EV/EBITDA ratio of Maravai LifeSciences (MRVI) on the financial timeline demonstrates business value dynamics, where 120.86 captures the magnitude of this parameter. Demand for RNA therapy components is growing due to new gene programs. CleanCap technology ensures high margins and robust protection of market positions. Meanwhile, Maravai LifeSciences outsources a portion of its laboratory processes and biomaterial logistics to external contractors.
Summary analytical data breakdowns for Maravai LifeSciences Holdings, Inc. (MRVI)
- stock price and consensus target price:
- company stock capitalization data:
- book value of equity indicators:
- company liabilities and liquidity data:
Debt to Equity Maravai LifeSciences|MRVI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Maravai LifeSciences Holdings|MRVI - Company Aggregate Debts|Debt to Book Capitalization Ratio Maravai LifeSciences Holdings|MRVI - Company Long-Term Loans and Borrowings|Company Short-Term Debts Maravai LifeSciences|Quick Liquidity Indicator maravai.com
- financial results and valuation multiples details:
MRVI - Company Net Income|Projected Future Earnings Maravai LifeSciences|MRVI - P/E Multiple|Forward P/E Multiple Maravai LifeSciences Holdings|MRVI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Maravai LifeSciences Holdings|MRVI - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Maravai LifeSciences|MRVI - Earnings per share for the last twelve months|Quarterly EPS earnings growth maravai.com|MRVI - Expected net earnings per share growth this year|Earnings growth forecast for next year Maravai LifeSciences
- sales volume and revenue indicators:
Fundamental company analysis:MRVI (Maravai LifeSciences)
For Maravai LifeSciences (MRVI), which is pivoting its nucleic acid production from COVID-related volumes toward the long-term mRNA therapy market, assessing the total enterprise value relative to operating profit is critical. By analyzing the EV/EBITDA multiple chart, an investor compares market capitalization and debt against actual earnings to determine whether the current price reflects an undervaluation or growing debt service risks.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization agilent.com A|Total Company Value to Operating Income Before Depreciation Ratio Quest Diagnostics (DGX)|ILMN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Exact Sciences Corporation EXAS|RVTY: EV/EBITDA Multiple|BIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization anbio.com|soterahealth.com (SHC) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization quidel.com (QDEL)|OPK: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CDNA (CareDx Corp)|EV/EBITDA Multiple Fulgent FLGT|LAB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Cytek Biosciences, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|OraSure Technologies, Inc. (OSUR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Exagen Diagnostics (XGN)|MDXH (mdxhealth.com) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation LUCD (Lucid Diagnostics Inc.)|EV/EBITDA Multiple PRE|IMDX (Insight Molecular) - Business Value to Operating Income Before Depreciation|Trinity Biotech - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio ProPhase Labs (PRPH)|AIMD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CODX (CoDx) - Enterprise Value to Operating Income Before Depreciation|heartsciences.com (HSCS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Biomerica (BMRA) - EV/EBITDA Multiple|CDIO (Cardio Diagnostics Holdings, Inc.) - EV/EBITDA Multiple|ONCO: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VRAX|EV/EBITDA Multiple Bluejay (BJDX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aspirawh.com AWH|AXDX: Enterprise Value to Operating Income Before Depreciation|CNTG: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Enzo Biochem ENZ|Fresh2 Group (FRES) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA GTG Labs (GENE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 23andMe Holding Co|Enterprise Value to EBITDA Ratio Psychemedics (PMD)
